PP
REGN icon

PFS Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

PFS Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15K Hold
24
– – 0.01% 342
2026
Q1 		$18.6K Hold
24
– – 0.01% 287
2025
Q4 		$18.6K Hold
24
– – 0.01% 289
2025
Q3 		$13.5K Buy
24
+10
+71% +$5.65K 0.01% 309
2025
Q2 		$7.37K Hold
14
– – ﹤0.01% 351
2025
Q1 		$8.89K Hold
14
– – ﹤0.01% 299
2024
Q4 		$9.97K Hold
14
– – 0.01% 289
2024
Q3 		$14.7K Hold
14
– – 0.01% 247
2024
Q2 		$14.7K Hold
14
– – 0.01% 228
2024
Q1 		$13.5K Hold
14
– – 0.01% 242
2023
Q4 		$12.3K Hold
14
– – 0.01% 246
2023
Q3 		$11.5K Hold
14
– – 0.01% 231
2023
Q2 		$10.1K Buy
+14
New +$10.8K 0.01% 264

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

PFS Partners's REGN Position: Q2 2026 in Review

PFS Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 24 shares worth $15K. The position accounts for 0.01% of the portfolio, ranked #342.

PFS Partners first reported a position in REGN in Q2 2023 and has held it in 13 quarters since. The position peaked at $18.6K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • PFS Partners held 24 shares of Regeneron Pharmaceuticals worth $15K as of Q2 2026.
  • PFS Partners left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.01% of PFS Partners's portfolio in Q2 2026, its #342 holding.
  • PFS Partners first reported a position in Regeneron Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • PFS Partners's Regeneron Pharmaceuticals position peaked at $18.6K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on PFS Partners's 13F filing for Q2 2026, filed 20 Jul 2026.